期刊
EXPERT REVIEW OF HEMATOLOGY
卷 3, 期 5, 页码 527-535出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/EHM.10.53
关键词
anticoagulant; antithrombin; argatroban; cardiovascular disease; direct thrombin inhibitor; heparin-induced thrombocytopenia; ischemic stroke; percutaneous coronary intervention
类别
Argatroban is a synthetic, small-molecule direct thrombin inhibitor that is approved in the USA, the EU and Japan for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT), and for anticoagulation of HIT patients undergoing PCI. Argatroban binds reversibly to, and inhibits both soluble and clot-bound thrombin. Argatroban does not generate antibodies, is not susceptible to degradation by proteases and is cleared hepatically. It has a predictable anticoagulant effect and there is a good correlation between dose, plasma concentration and pharmacodynamic effect. Initial clinical studies suggest that further investigations to establish the use of argatroban in ischemic stroke, acute coronary syndrome, hemodialysis, blood oxygenation, off-pump cardiac surgery and other clinical indications are warranted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据